LIB Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a novel, effective, safe and convenient injectable and oral PCSK9 inhibitors to the millions of patients with CVD or at very high or high risk of CVD who require additional large reductions in LDL-C despite maximally tolerated statins and other oral lipid lowering agents. Based in Cincinnati, LIB Therapeutics is a privately funded company.